Manufactured by:ProteoGenix
Save 20%RUO

MOR014824 Biosimilar – Anti-TSLP mAb – Research Grade

MOR014824 Biosimilar – Anti-TSLP mAb – Research Grade from ProteoGenix; catalogue PX-TA1905; research use only.

SKU:
ABM134153-1
Manufacturer SKU
PX-TA1905
Product type
Primary Antibodies
TargetMOR014824 Biosimilar – Anti-TSLP mAb – Research Grade
ApplicationsELISA, WB
Expression systemXtenCHO

Manufacturer provenance

Manufactured by:
ProteoGenix
Sold by:
ABMIUM
Fulfilled from:
Manufacturer facility or confirmed fulfilment location

Know who made it. See the evidence. Buy through one marketplace.

Product description

The Structure of MOR014824 Biosimilar – Anti-TSLP mAb

MOR014824 Biosimilar – Anti-TSLP mAb is a monoclonal antibody (mAb) that specifically targets the cytokine thymic stromal lymphopoietin (TSLP). It is a biosimilar version of the original anti-TSLP mAb, designed to have a similar structure and function.

The antibody is composed of two identical heavy chains and two identical light chains, which are connected by disulfide bonds. Each chain consists of constant and variable regions. The variable regions are responsible for binding to TSLP, while the constant regions determine the antibody’s effector functions.

The Activity of MOR014824 Biosimilar – Anti-TSLP mAb

TSLP is a cytokine that plays a crucial role in the regulation of immune responses and inflammation. It is produced by various cell types, including epithelial cells, dendritic cells, and mast cells. TSLP binds to its receptor, which is composed of the TSLP receptor (TSLPR) and the IL-7 receptor alpha chain (IL-7Rα), to activate downstream signaling pathways.

MOR014824 Biosimilar – Anti-TSLP mAb specifically binds to TSLP and blocks its interaction with the TSLPR/IL-7Rα receptor complex. This prevents the activation of downstream signaling pathways and inhibits the pro-inflammatory effects of TSLP. By neutralizing TSLP, MOR014824 Biosimilar – Anti-TSLP mAb can reduce inflammation and modulate immune responses.

The Application of MOR014824 Biosimilar – Anti-TSLP mAb

MOR014824 Biosimilar – Anti-TSLP mAb has potential therapeutic applications in various inflammatory and autoimmune diseases. TSLP has been implicated in the pathogenesis of conditions such as asthma, atopic dermatitis, and inflammatory bowel disease. By targeting TSLP, MOR014824 Biosimilar – Anti-TSLP mAb can potentially alleviate symptoms and improve outcomes in these diseases.

In addition, TSLP has been shown to play a role in cancer progression and metastasis. It promotes tumor growth and angiogenesis, as well as suppresses anti-tumor immune responses. Therefore, MOR014824 Biosimilar – Anti-TSLP mAb may also have potential as an anti- cancer therapy.

Furthermore, MOR014824 Biosimilar – Anti-TSLP mAb can be used as a research tool to study the role of TSLP in various diseases and to develop new therapeutic strategies targeting this cytokine.

Conclusion

In summary, MOR014824 Biosimilar – Anti-TSLP mAb is a monoclonal antibody that specifically targets the cytokine TSLP. It blocks the interaction between TSLP and its receptor, thereby inhibiting pro-inflammatory effects and modulating immune responses. This biosimilar version of the original anti-TSLP mAb has potential therapeutic applications in inflammatory and autoimmune diseases, as well as in cancer. It can also serve as a valuable research tool in the study of TSLP.

ProteoGenix catalogue number PX-TA1905. For research use only.

Target: MOR014824 Biosimilar – Anti-TSLP mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.

Available configurations: 50ug, 100ug, 1mg.

Download the manufacturer datasheet

Download the manufacturer safety data sheet (MSDS/SDS)

Key facts & specifications
Also known as
anti-TSLP,Thymic stromal lymphopoietin,
Clonality
Monoclonal
Isotype
IgG2-kappa(Slience)
Source organism
Human
Sequence
MFPFALLYVLSVSFRKIFILQLVGLVLTYDFTNCDFEKIKAAYLSTISKDLITYMSGTKSTEFNNTVSCSNRPHCLTEIQSLTFNPTAGCASLAKEMFAMKTKAALAIWCPGYSETQINATQAMKKRRKRKVTTNKCLEQVSQLQGLWRRFNRPLLKQQ
Technical note
For research use only. Not suitable for clinical or therapeutic use.
Validation & performance evidence
ABMIUM Validated™ ABMIUM Verified™ Expected performance Not suitable

Application validation

Evidence status by application and model.

TargetWBIHC-PIHC-FrIF/ICCFlow CytIPChIPELISA
MOR014824 Biosimilar – Anti-TSLP mAb – Research Grade
Identifiers & database references
Manufacturer SKU
PX-TA1905
UniProt accession
Q969D9
Storage, stability & shipping
Storage conditions
store at -80°C
Shipped at
Blue ice (+4°C)
Compliance & documents
ISO certifications
ISO 9001:2023, ISO 14001: 2023
Datasheet
Open datasheet
Safety data sheet
Open SDS
Frequently asked questions
Who manufactured this product?

This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.

Can ABMIUM ship this product internationally?

ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.

Can I check suitability before ordering?

Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.

Is this product for clinical use?

Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.

ProteoGenix
£149.00£119.20